At Xiamen Innovax, women are playing a leading role in advancing vaccine innovation and expanding access to cervical cancer prevention.

This commitment was recently recognized when the company received the National March 8th Red-Banner Collective, a national honor awarded by the All-China Women's Federation to organizations demonstrating outstanding contributions by women.

The recognition highlights the important role women play across Xiamen Innovax’s research, manufacturing, and quality teams—and their contributions to the development of innovative HPV vaccines designed to protect women’s health.

Advancing Cervical Cancer Prevention Through Innovation

Cervical cancer is the fourth most common cancer among women worldwide and remains a major threat to women’s health. Importantly, it is one of the few cancers that can be effectively prevented through vaccination. As a result, expanding access to HPV vaccination and eliminating cervical cancer have become key global public health priorities.

Building on this platform, Xiamen Innovax’s bivalent HPV vaccine Cecolin has been incorporated into immunization programs in multiple countries, contributing to increased vaccination coverage, particularly in developing regions.

In 2025, the HPV nine-valent vaccine Cecolin 9, co-developed by Xiamen Innovax and Xiamen University, received regulatory approval in China. As the second HPV nine-valent vaccine available globally, this milestone represents an important technological advancement in higher-valency HPV vaccine development and expands vaccine options for women.

Both vaccines are built on Xiamen Innovax’s E. coli–derived virus-like particle (VLP) platform, an innovative technology developed through years of research and collaboration. Clinical trials for the HPV nine-valent vaccine enrolled more than 10,000 women aged 9–45, and head-to-head studies with imported vaccines demonstrated comparable immunogenicity and safety profiles.

Women Powering Vaccine Development and Manufacturing

Women represent more than 60% of Xiamen Innovax’s workforce, contributing expertise across the entire vaccine innovation lifecycle.

Within R&D teams, female scientists have led critical technical breakthroughs with professionalism and perseverance. Across manufacturing operations, teams rigorously implement 132 precise production procedures and 367 quality-control standards, ensuring consistent product quality and reliable vaccine supply.

Stable production capacity and internationally aligned quality standards have helped address previous supply constraints in the HPV vaccine market, enabling more women to access timely protection.

In quality management, female professionals maintain rigorous standards aligned with international regulatory systems to safeguard the safety and effectiveness of every vaccine dose.

Inspiring the Next Generation of Women in Science

Prior to receiving the National March 8th Red-Banner Collective honor, Xiamen Innovax’s HPV vaccine manufacturing team had also received provincial-level recognition for excellence among women-led teams.

These recognitions highlight the dedication, expertise, and leadership of women who continue to drive innovation in vaccine development.

Looking ahead, Xiamen Innovax remains committed to advancing next-generation HPV vaccine technologies and contributing scientific innovation to improve women’s health in China and globally.

At Xiamen Innovax, we believe scientific innovation and the leadership of women in science can help build a future where preventable diseases no longer threaten women’s health—advancing protection, expanding access, and safeguarding the health of generations to come.